Trial Profile
A phase II study to assess the efficacy and safety of front-line combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNα2b) therapy in patients newly diagnosed with chronic phase chronic myeloid leukaemia (CP-CML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2020
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Peginterferon alfa-2b
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms DASA-PEGIFN
- 21 Jun 2020 Status changed from recruiting to completed, according to results presented at the 25th Congress of the European Haematology Association
- 21 Jun 2020 Results of 48 months follow-up presented at the 25th Congress of the European Haematology Association
- 08 Dec 2015 Preliminary results (n=81) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology